EUVIMEDEUVIMED entdecken
Crossref

A patient with atopic dermatitis with poor disease control and conjunctivitis during dupilumab treatment who was successfully switched to baricitinib

Takahiro Kiyomasu, Tatsuya Sakaki, Saki Yamada, Chonsu Kim, Yukiko Hiraguchi

Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology · 20.03.2026 · 40 (1) · 17-22

DOI: 10.3388/jspaci.40.17 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology, erschienen am 20.03.2026. Verfasst von Takahiro Kiyomasu und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kiyomasu, T., Sakaki, T., Yamada, S., Kim, C., & Hiraguchi, Y. (2026). A patient with atopic dermatitis with poor disease control and conjunctivitis during dupilumab treatment who was successfully switched to baricitinib. Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology, 40(1), 17-22. https://doi.org/10.3388/jspaci.40.17

Vancouver

Kiyomasu T, Sakaki T, Yamada S, Kim C, Hiraguchi Y. A patient with atopic dermatitis with poor disease control and conjunctivitis during dupilumab treatment who was successfully switched to baricitinib. Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology. 2026;40(1):17-22. doi:10.3388/jspaci.40.17

BibTeX
@article{Kiyomasu2026,
  author = {Kiyomasu, Takahiro and Sakaki, Tatsuya and Yamada, Saki and Kim, Chonsu and Hiraguchi, Yukiko},
  title = {A patient with atopic dermatitis with poor disease control and conjunctivitis during dupilumab treatment who was successfully switched to baricitinib},
  journal = {Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {17--22},
  doi = {10.3388/jspaci.40.17}
}
Kostenlos starten →